^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BI 1387446

    i
    Other names: BI 1387446, BI-1387446
    Associations

    News

    Trials
    Company:
    Boehringer Ingelheim
    Drug class:
    STING agonist
    Related drugs:
    Associations

    News

    Trials
    9ms
    A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors) (clinicaltrials.gov)
    P1, N=39, Completed, Boehringer Ingelheim | Active, not recruiting --> Completed
    Trial completion
    |
    ezabenlimab (BI 754091) • BI 1387446
    4years
    [VIRTUAL] Phase I, first-in-human trial evaluating BI 1387446 (stimulator of interferon genes [STING] agonist) alone and combined with BI 754091 (anti-programmed cell death [PD]-1) in solid tumors (SITC 2020)
    The trial is currently open for recruitment. Results N/A Conclusions N/A
    P1 data
    |
    STING (stimulator of interferon response cGAMP interactor 1)
    |
    ezabenlimab (BI 754091) • BI 1387446
    4years
    [VIRTUAL] Phase I, first-in-human trial evaluating BI 1387446 (stimulator of interferon genes [STING] agonist) alone and combined with BI 754091 (anti-programmed cell death [PD]-1) in solid tumors (SITC 2020)
    The trial is currently open for recruitment. Results N/A Conclusions N/A
    P1 data
    |
    STING (stimulator of interferon response cGAMP interactor 1)
    |
    ezabenlimab (BI 754091) • BI 1387446